SOLENO THERAPEUTICS INC

Soleno Therapeutics has voluntarily withdrawn the approval application for VIOKAT extended‑release tablets (diazoxide‑choline) in Europe. The company cited business and strategic considerations and left open the possibility of resubmitting the application at a later date if a suitable path emerges. The decision follows previously anticipated reviews by the EMA and concerns the treatment of patients with Prader‑Willi syndrome and hyperphagia. » Más en de.investing.com

Neurocrine will buy Soleno via a $53 per share cash tender offer, implying an enterprise value of about $2.9 billion, funded with cash and modest pre‑payable debt and expected to be immediately accretive in 2026. Management highlighted Vykat XR, approved for hyperphagia in Prader‑Willi syndrome, which generated roughly $190 million in 2025 and targets a defined ~10,000‑patient U.S. market with asserted exclusivity into the mid‑2040s. Neurocrine plans a U.S.‑focused commercial rollout emphasizing clinician education, community reach and strong early reimbursement, and currently has no plans to launch in Europe. » Más en finance.yahoo.com

Oppenheimer cut its price target on Soleno Therapeutics from $110 to $80, citing a slower U.S. launch ramp and a shift to standalone European commercialization, but kept an Outperform rating and projects 2026 revenue above consensus. Wells Fargo trimmed its target slightly to $110 while maintaining an Overweight rating, calling the shares cheap relative to projected FY2026 revenue and cash flows despite concerns about pipeline comments and the CFO retirement. Soleno began U.S. commercialization of VYKAT XR in April 2025 and remains a clinical-stage developer focused on rare diseases like Prader-Willi Syndrome, with upcoming catalysts expected to support the shares. » Más en finance.yahoo.com